Clinical Policy: Cardiac Biomarker Testing
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.156 alerts
Get alerted when Policy CP.MP.156 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coding stance for cardiac biomarker testing used to evaluate suspected acute myocardial infarction or myocardial injury for members of health plans affiliated with Centene Corporation (applies to Arizona Complete Health).
No material clinical or coverage changes in this revision.
Coverage criteria for cardiac biomarker testing
Medical necessity determinations
From policy section I
From policy section II
CK-MB (CPT 82553) and myoglobin (CPT 83874) are considered not medically necessary when used in the evaluation for suspected acute myocardial infarction (AMI), particularly when troponin testing (CPT 84484) is performed. This policy applies to members of health plans affiliated with Centene Corporation, including Arizona Complete Health, and reflects the recommendation that troponin I or T is the appropriate primary cardiac biomarker for suspected AMI.
CK-MB and myoglobin testing are explicitly described as not medically necessary for the evaluation of suspected AMI because troponin I or T assays are the recommended biomarker due to their superior sensitivity and accuracy. Billing CPT 82553 or CPT 83874 with CPT 84484 (troponin) may be considered not medically necessary and is subject to denial; documentation must support medical necessity for any additional cardiac biomarker testing beyond troponin.
Relevant CPT codes and coding guidance
Provider billing, documentation, and prior-authorization guidance
Provider billing, documentation, and prior-authorization guidance
When troponin testing (CPT 84484) is used as the cardiac biomarker for evaluation of suspected acute myocardial infarction or myocardial injury, providers should document clinical indications supporting medical necessity for any additional biomarker testing. Routine use of CK‑MB (CPT 82553) or myoglobin (CPT 83874) in addition to troponin is not considered medically necessary and may be subject to denial.
- Preferred biomarker: Troponin (CPT 84484) — no prior step-therapy sequencing required; troponin is the established preferred test.
- Not medically necessary when billed with CPT 84484: CPT 82553 (CK‑MB) and CPT 83874 (myoglobin).
- Documentation requirement: If CPT 82553 or CPT 83874 is billed in addition to CPT 84484, the medical record must clearly justify the medical necessity for additional biomarker testing (e.g., specific clinical scenario where troponin alone is insufficient).
- Denial risk: Billing CPT 82553 or CPT 83874 together with CPT 84484 may be denied as not medically necessary.
Key definitions
Clinical background and rationale
Cardiac troponins I and T are the preferred biomarkers for diagnosis of acute coronary syndromes and myocardial injury because they have superior sensitivity and specificity compared with older markers such as CK-MB and myoglobin. Historically, CK-MB and myoglobin were used to detect AMI, but evidence and guideline-based practice support omitting these tests in the initial evaluation when troponin testing is available because they do not add diagnostic value beyond troponin.
Policy revision history
Policy reviewed as part of routine annual review; clinical stance affirms troponin I/T as medically necessary and CK-MB and myoglobin as not medically necessary for evaluation of suspected AMI.
CPT code table updated to list CPT 82553 (CK-MB) and CPT 83874 (myoglobin) as not medically necessary when billed with CPT 84484 (troponin).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.